Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

ATR12-351 · ATR-12

Microbiome therapy · developed by Azitra

Phase 1 Most advanced trial (none active)

AZTR Developer

1 Registered trials

What is ATR12-351?

ATR12-351 is a topical ointment containing a LEKTI-secreting strain of Staphylococcus epidermidis, a skin commensal bacterium engineered to secrete the LEKTI protein. It is being studied in Netherton Syndrome, a rare inherited skin disorder.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: ATR-12
Drug type: Microbiome therapy
Therapy area: Dermatology
Developer: Azitra Inc. (AZTR)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06137157	Phase 1	Netherton Syndrome	Completed	AZTR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Netherton Syndrome

More from Azitra

ATR-04 Phase 1/2

Sources

ClinicalTrials.gov NCT06137157

Updated Oct 11, 2026. Something wrong or missing? Report it on the AZTR page.

Follow AZTR, the company behind ATR12-351

See AZTR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AZTR catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z